JANX-008

N/A

Report date: 2026/03/19 17:16:37

Base Information

Drug NameJANX-008
Drug Alias NameJANX008EGFR-TRACTrJANX-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnti-CD3
TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesJanux Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesJanux Therapeutics IncMerck KGaA, Darmstadt, Germany
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A